European journal of breast health最新文献

{"title":"One-Stop Contrast-Enhanced Mammography-Guided Breast Biopsy: A Practical Workflow from a Tertiary Referral Center.","authors":"Hülya Özdemir, Umur Anıl Pehlivan, Hüseyin Özgür Aytaç","doi":"10.4274/ejbh.galenos.2026.2026-1-13","DOIUrl":"10.4274/ejbh.galenos.2026.2026-1-13","url":null,"abstract":"","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"22 4","pages":"520-522"},"PeriodicalIF":2.1,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13599746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149032253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Ratio of the Resected Specimen Volume to Breast Volume, as Measured by Three-Dimensional Surface Imaging, Is Associated With Aesthetic Outcome After Breast-Conserving Surgery.","authors":"Satsuki Fukumoto, Hironori Goto, Yukiko Hara, Keiichiro Tada","doi":"10.4274/ejbh.galenos.2026.2026-5-6","DOIUrl":"10.4274/ejbh.galenos.2026.2026-5-6","url":null,"abstract":"<p><strong>Objective: </strong>An objective method to predict aesthetic outcomes after breast-conserving surgery (BCS) has not been established. The ratio of the resected specimen volume to breast volume (S/B ratio) may be a reasonable option for this purpose.</p><p><strong>Materials and methods: </strong>We recruited 32 breast cancer patients who underwent BCS. Preoperative breast volumes were measured using three-dimensional surface imaging (3DSI) and computed tomography (CT). The volume of the surgical specimens was estimated by the length, width, and height of the specimen. The S/B ratio was calculated from these values. The association between the S/B ratio and aesthetic outcome evaluated by an expert panel or by patient-reported outcomes was analyzed 1 year after BCS.</p><p><strong>Results: </strong>There was a statistically significant association between the S/B ratio and aesthetic outcome evaluated by the expert panel when we used 3DSI to measure the preoperative breast volume (<i>p</i> = 0.01). An S/B ratio of <12.3% may represent a preliminary cut-off for predicting an excellent aesthetic outcome. This association was not observed when CT was used to measure breast volume (<i>p</i> = 0.09). Furthermore, there was no significant association between the S/B ratio and patient-reported outcome.</p><p><strong>Conclusion: </strong>When 3DSI is used for breast volume measurement, the S/B ratio is associated with the aesthetic outcome after BCS. This advantage of 3DSI may be due to the upright position of the patients during the breast volume measurement.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"22 4","pages":"447-454"},"PeriodicalIF":2.1,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13599762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149026986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Reach and Educational Impact of a Public Oncology Webinar Series in South Africa: A Model for Accessible Cancer Education.","authors":"Dom Van Loggerenberg","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Accessible, community-driven education is critical to improving early detection and survivorship outcomes in breast cancer. The Breast Care Centre of Excellence (BCCE) in South Africa launched a webinar series in 2025 to raise public awareness and support survivorship education. This study evaluates the programme's community reach, engagement, and responsiveness with the aim of guiding future digital education initiatives in oncology to increase community awareness.</p><p><strong>Materials and methods: </strong>A retrospective analysis of 14 webinars held between January and October 2025 was conducted. Engagement metrics included registrations (n = 1,731), live attendance (n = 1,179), public reach via information-page interactions (n = 9,073), and unique on-demand views (n = 733). Attendance trends and engagement were analysed.</p><p><strong>Results: </strong>Across 14 sessions, 1,179 live attendees were recorded from 1,731 registrations, a 68.1% conversion rate. The programme achieved substantial public visibility, with 9,073 page interactions, indicating strong community interest beyond direct attendees. Unique views (n = 733) represented a 59.3% extended reach beyond live participation, extending educational access over time. This is significant, as only 70% of the webinars were made available for on-demand viewing after the event, further reinforcing the programme's reach. Webinars on nutrition and personalised oncology generated the highest engagement and sustained replay interest, highlighting demand for practical, actionable, and lifestyle-relevant oncology education.</p><p><strong>Conclusion: </strong>The BCCE's public oncology webinar series represents a cost-effective, scalable, and culturally adaptive model for cancer education in low- and middle-income settings. High registration-to-attendance conversion, broad community reach, and sustained asynchronous engagement demonstrate durable audience interest and growing public trust. Future programmes will incorporate structured follow-up surveys to measure knowledge retention and behavioural change at 4-6 weeks, and expand cross-disciplinary sessions (e.g., oncology × nutrition) to deepen educational continuity and impact.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"22 3","pages":"1"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148280526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NQMBC Crosses the Ocean: A Quality Program Adopted in China.","authors":"Cary S Kaufman, Ayfer K Polat, Ramadha Piyadi Gamage, Aerial Gilbert, Kimberly Bolin","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>The National Quality Measures for Breast Centers (NQMBC) originated as an idea in 2003 by the National Consortium of Breast Centers (NCBC) board who felt that increased attention was warranted, initiated by the institute of medicine, to measure, evaluate and improve the quality of breast cancer care. To serve the widespread membership of NCBC, any quality assessment program would need to be web-based so that no matter where your breast center was located, your center could assess their own level of their quality care performance. The focus of quality performance was on the level of care actually delivered for each performance measure. The NQMBC is a set of quality measures including each discipline in the breast center; imaging, surgery, pathology, medical oncology, radiation oncology, genetics, navigation and the newly added inflammatory breast cancer.</p><p><strong>Materials and methods: </strong>The NQMBC looks at real time data from participating breast centers across the country. Once a center's data on a particular is entered into the NQMBC, the website immediately provides comparisons with other centers' performance. The results show the submitted center's data and the comparison 25th, 50th and 75th percentile performance of all the other centers who have submitted data on that measure. A center can identify the level of performance on that specific measure and decide whether improvement is neded or congratulations is deserved. All data is confidential and hot shared with any other center. No patient data is used.</p><p><strong>Results: </strong>Recently a government grant was awarded to a group headed by Aurora Inc., striving to improve the quality of care provided in China. Experts in breast cancer care were identified to aid in this effort. Many clinicians from China have been sent for two-month observerships to Montefiore-Einstein Medical Center to see how the US approaches breast cancer. To assess the quality of care provided, the NQMBC was chosen to assess the resultant quality of care it in at least three large breast centers in China. In-person exchanges occurred this last month to initiate the integration of NQMBC as a measure of their quality breast cancer care. Goals of these three facilities is to achieve the level of a quality breast center of excellence.</p><p><strong>Conclusion: </strong>Three main medical centers in three separate provinces, each serving a population of over 100 million, have agreed to integrate the NQMBC quality program as a measure of their breast care. This long-term pilot program has positive implications to improve the level of breast care in China, and a valuable extension of the international use of NQMBC.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"22 3","pages":"2"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148280593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypofractionated Radiation Therapy for Breast Cancer: A Unit Review in Alignment with International Guidelines.","authors":"Dom Van Loggerenberg","doi":"","DOIUrl":"","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;Randomized trials and international guidelines endorse hypofractionated whole-breast irradiation (HF-WBI) as standard of care for early breast cancer, offering equivalent tumour control with shorter treatment times and reduced system burden. In South Africa, where access and throughput are critical, real-world uptake is particularly relevant. This review evaluates our centre's adoption of HF-WBI and adherence to guideline-based practice.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;We retrospectively reviewed all breast cancer patients referred for radiotherapy from 2018-2024, stratifying fractionation as conventional WBI (CF-WBI; ~50 Gy/25 fractions), hypofractionation (40.05 Gy/15 or 42.5 Gy/16), and ultra-hypofractionation (≈26 Gy/5). Among those receiving breast-conserving therapy (BCT), we assessed annual HF-WBI adoption, age distribution (&lt;50 vs. ≥50 years), and boost use.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Across yearly datasets, HF-WBI increased steadily and substantially. In 2018, HF-WBI accounted for 17/138 CF/HF cases (12.3%). Uptake rose through 2019 (21.0%), 2020 (27.1%), 2021 (43.4%), 2022 (38.6%), 2023 (54.6%), and reached 82.4% in 2024 (103 HF vs. 22 CF). Ultra-hypofractionation (≈26 Gy/5) appeared from 2022 onward at low but increasing levels (e.g., 6 cases in 2024). Boost delivery was used across schedules; HF-WBI frequently included a boost (e.g., 59 cases in 2023; 70 in 2024), indicating protocol flexibility without abandoning shorter courses. Importantly, HF-WBI was used in both younger and older patients (e.g., 2024: &lt;50 y = 32; ≥50 y = 70 within HF cases), reflecting rising clinician confidence across age groups as guideline-concordant practice matured.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Our multi-year review demonstrates a decisive transition from conventional to HF breast RT, with HF-WBI becoming the predominant regimen by 2024. Real-world implementation was feasible with sustained boost utilisation and broad age inclusivity, aligning with international guidelines while improving patient convenience and departmental efficiency. Wider adoption of HF-WBI-and selective use of ultra-hypofractionation- can expand equitable access and support service sustainability in resource-constrained health systems.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Recommendations: &lt;/strong&gt;1. Adopt \"HF-by-default\" for eligible BCT patients, requiring a documented exception for CF-WBI. 2. Scale a FAST-Forward pathway (≈26 Gy/5) where clinically appropriate with clear selection criteria. 3. Standardise boost indications in HF schedules (e.g., 10-16 Gy in 4-8 fractions). 4. Embed age-agnostic eligibility in MDM checklists to avoid age-based bias against HF. 5. Bundle HF-WBI with DIBH planning QA for left-sided cases to maintain cardiac/lung constraints. 6. Implement a KPI dashboard tracking HF share, median treatment days, boost rate, and re-planning rate. 7. Update patient-facing education to explain HF schedules and boost delivery, improving adhe","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"22 3","pages":"14"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148280524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Cancer-related Lymphedema: A Comparative Ultrasound Study of Shear Wave Elastography and B-mode Measurements for Assessing Lymphaticovenous Anastomosis.","authors":"Zohaib Lakhani, Samuel Jang, Matthew W Urban, Vahe Fahradyan, Nho Tran, Luiz Vasconcelos, Kate Knoll, Jenny Bradt, Matthew Johnson, Christine Lee","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Lymphedema grading relies on subjective and indirect objective measures. Ultrasound shear wave elastography (SWE) provides a quantitative, non-invasive assessment of tissue stiffness (Young's modulus, E), which may reflect disease severity and improve objectivity in staging lymphedema. This pilot study (NCT05613946) evaluates the utility of SWE and B-mode skin and subcutaneous thickness for grading upper extremity lymphedema in patients with treated breast cancer undergoing lymphaticovenous anastomosis (LVA) surgery.</p><p><strong>Materials and methods: </strong>Nine patients with upper extremity lymphedema secondary to breast cancer underwent ultrasound preoperatively (baseline) and six months following LVA. Soft tissue thickness and stiffness were measured in the affected limb and contralateral unaffected limb (control). Imaging findings were correlated with routinely collected objective metrics, including limb volume and bioimpedance spectroscopy.</p><p><strong>Results: </strong>At baseline, the affected limb demonstrated slightly lower soft tissue stiffness than the unaffected limb (mean dermal E: 75.4±10.6 kPa vs. 78.0±12.8 kPa; mean subcutaneous E: 40.8±17.7 KPa vs. 45.5±19.5 KPa). At six-month follow-up, dermal and subcutaneous stiffness increased, on average more in the untreated limb. Post-operative changes in stiffness showed weak to moderate positive correlation with changes in arm volume (dermal E: slope (m) = 0.02, R² = 0.37, subcutaneous E: slope (m) = 0.01, R² = 0.14) and no correlation with electrical impedance. Baseline dermal and subcutaneous thickness were similar between limbs. At six-month follow-up, dermal and subcutaneous thickness also increased in both arms. Treated limb volume decreased (mean Δ: -276.3±326.1 mL) and impedance increased (mean Δ: +14.7±22.3 Ohms), consistent with clinical improvement.</p><p><strong>Conclusion: </strong>Postoperative increased in dermal stiffness and soft tissue thickness were not intuitive. Potential confounders that could explain this result include increased patient weight or variability in sonographic technique. The increasing trend for subcutaneous stiffness is noted in the literature and may be due to underlying chronic fibrosis. Additional research is warranted to clarify the role of SWE and B-mode measurements in lymphedema assessment.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"22 3","pages":"10"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148279776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Clinical and Pathological Tumour Staging Following CDK4/6 Inhibitor-based Neoadjuvant Therapy in HR+/HER2- Breast Cancer.","authors":"Dom Van Loggerenberg","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>CDK4/6 inhibitors are an established component of systemic therapy for hormone receptor-positive (HR+)/HER2- breast cancer, with proven efficacy in combination with endocrine therapy in both advanced and early-stage disease. Their role in the neoadjuvant setting is increasingly explored, particularly for patients in whom chemotherapy may be less appropriate. This study evaluated the impact of CDK4/6 inhibitor-based neoadjuvant therapy on clinical-to-pathological tumour stage conversion and assessed biological subtype modulation before and after treatment.</p><p><strong>Materials and methods: </strong>This retrospective analysis included 92 patients (96 tumours, including four multifocal or bilateral cases) treated at a high-volume multidisciplinary breast unit. All patients received a CDK4/6 inhibitor combined with endocrine therapy, most commonly aromatase inhibitors ± GnRH agonists, as neoadjuvant systemic treatment. Tumour biology was assessed using standard immunohistochemistry for estrogen receptor, progesterone receptor, and HER2, with molecular subtypes classified according to St Gallen 2019 criteria. Clinical tumour stage (initial T) was compared with final pathological stage (final T) to assess downstaging. Ki-67 proliferation indices were recorded on core biopsy and final pathology.</p><p><strong>Results: </strong>Pathological complete response (pCR) was observed in five tumours (5.2%), including one breast in a bilateral case. At baseline, Luminal B was the predominant subtype (53.1%), followed by Luminal A (41.7%), with HER2-equivocal tumours accounting for 5.2%. Following neoadjuvant therapy, Luminal A increased to 76.0% while Luminal B decreased to 11.5%, indicating marked biological differentiation and enhanced endocrine responsiveness. One Luminal B tumour converted to a triple-negative phenotype. HER2-equivocal tumours (n = 6) persisted without further SISH confirmation. On core biopsy, only 10 patients demonstrated a Ki-67 ≤6%. Post-treatment pathology revealed a substantial reduction in proliferative activity, with 53 patients showing Ki-67 <3%, including four with <1%. A parallel reduction in tumour size and stage was observed, with most tumours demonstrating downward T-stage migration (e.g., T3-T4 to T1-T2).</p><p><strong>Conclusion: </strong>CDK4/6 inhibitor-based neoadjuvant therapy results in meaningful tumour downstaging and biological subtype modulation in HR+/HER2- breast cancer. The frequent conversion from Luminal B to Luminal A and the marked suppression of Ki-67 support the cytostatic, differentiation-driven mechanism of CDK4/6 inhibition. Although pCR rates remain modest compared with chemotherapy, the consistent biological and morphological responses highlight this approach as a lower-toxicity alternative or complement to chemotherapy in selected patients. Prospective studies incorporating proliferative dynamics and nodal outcomes are warranted.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"22 3","pages":"13"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148280411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-centric Development of Shared Decision-making Aids: The ASSESS Online Personalized Early Breast Cancer Treatment Decision Support Tool and Resource Website.","authors":"Bethany A Kerr, J Doug Alexander, Hui Zhao, Michal Marczyk, Laura C Crocker, Alexandra A Erwin, Erica Kuhn, Hosea Baker, Sainath Vaidhyanath, Trevor Polischuk, Kimberly A Sabelko, Lajos Pusztai, Sharon H Giordano, Robert J Volk, Glendon M Zinser","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>People newly diagnosed with breast cancer spend a considerable amount of time researching their diagnosis, treatment options and associated side effects. Even with access to trusted evidence-based information, such as Susan G. Komen's About Breast Cancer pages (https://www.komen.org/breast-cancer/), patients and doctors may struggle to account for the many factors in an individual's diagnosis that influence treatment and outcomes, making it hard to balance the potential benefits of therapy with the risks of side effects on a personalized basis. The discontinuation of the popular adjuvant! Online tool compounded this challenge, creating a need for a new, publicly available tool to provide survival estimates for the U.S. early-stage breast cancer population.</p><p><strong>Materials and methods: </strong>Komen collaborated with teams from MD Anderson and Yale Cancer Centers to develop a web-based decision support tool that provides personalized five-year survival estimates for women with early-stage breast cancer. The tool, ASSESS, uses an algorithm developed with U.S.-based SEER data to estimate outcomes for various systemic adjuvant therapies based on an individual's clinical and pathological characteristics. The ASSESS online tool was designed and built by a multidisciplinary team of experts, including scientists, clinicians, website developers and marketing professionals, using an iterative approach to incorporate feedback from breast cancer patient advocates and clinicians. Initial design requirements for ASSESS included a simple, engaging user interface and a public-facing design suitable for clinical use as a shared decision-making tool. It was designed to be responsive and support use on multiple devices, incorporating best practices for communicating risks and offering a summary feature to save and print results. Cognitive interviews with patient advocates and breast cancer clinicians informed the tool's design, resulting in changes that made the interface and output clearer and more accessible to a lay audience. Once finalized, additional usability testing was conducted with patient advocates and breast cancer medical oncologists to ensure the tool was deployed as intended.</p><p><strong>Results: </strong>The ASSESS tool (www.komen.org/assess-tool), which was launched in December 2025, helps providers visually demonstrate outcomes for different treatment options and provides links to accessible information that can be shared with patients for each treatment, including details on how it works, its side effects, and references to the associated expert clinical guidelines.</p><p><strong>Conclusion: </strong>Built using a patient-centered approach, the ASSESS tool supports shared decision-making for people with early-stage breast cancer, helping them make the best individual decisions for their treatment and care.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"22 3","pages":"12"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148280606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing Breast Cancer Prevalence Among Female SDHx Pathogenic Variant Carriers in a Laboratory Research Registry.","authors":"Kimberly Van Ysseldyk, Monique Tiffany","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Germline pathogenic or likely pathogenic variants (PV/LPVs) in SDHx (SDHA, SDHB, SDHC, SDHD) cause hereditary paraganglioma and pheochromocytoma (PPGL) syndromes and are linked to other tumors, such as renal cell carcinoma (RCC) and gastrointestinal stromal tumors (GIST). As SDHx variants are increasingly identified on multigene panels, questions have arisen about a possible association with breast cancer (BC). Prior literature is mixed, underscoring the need for clearer characterization. This study assesses BC prevalence among female SDHx carriers in a large laboratory-based research registry.</p><p><strong>Materials and methods: </strong>We performed a retrospective cohort analysis using the Myriad Collaborative Research Registry (MCRR) v7. Females with a confirmed SDHx PV/LPV were included; those with co-occurring PV/LPVs in other cancer predisposition genes were excluded. Personal BC history was summarized overall and by gene. Indications for genetic testing were unavailable.</p><p><strong>Results: </strong>The MCRR includes 222,111 females with a personal history of cancer who underwent germline testing that included the SDHx genes; 135,712 (61%) had BC, with a mean diagnosis age of 57 years. Among all females tested, 508 SDHx PV/LPV carriers were identified. Of these, 286 (56.3%) had BC, including 7 with two primary BCs (293 total). Mean age at diagnosis among carriers was 57.4 years. By gene: • SDHA: 376 carriers; 218 (58%) with BC, 7 had 2 BC primaries. Mean age of diagnosis (dx): 57.4y • SDHB: 61 carriers; 32 (52.5%) with BC Mean age of dx: 55.2y • SDHC: 50 carriers; 25 (50%) with BC Mean age of dx: 58.8y • SDHD: 23 carriers; 11 (47.8%) with BC Mean age of dx: 60.5y Compared with the overall affected cohort, SDHx carriers had a lower proportion of BC (61% vs. 56.3%), with no gene specific enrichment and no evidence of earlier onset.</p><p><strong>Conclusion: </strong>In a large cohort of women with cancer who underwent multigene testing, SDHx PV/LPV carriers did not show higher BC prevalence than the overall group, and age at diagnosis was similar. The proportion of breast cancer in SDHx carriers was lower, but it remains unclear whether their risk differs from the general population or if findings are incidental. Since SDHx is often found incidentally, breast care teams should prioritize surveillance for tumors known to be associated with SDHx (PPGL, RCC, and GIST) and refer patients as appropriate to genetics or specialty care. Further prospective studies with cancer-free controls are needed to define breast cancer risk in SDHx carriers and guide screening.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"22 3","pages":"8"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148280270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Genetic Risk Assessment (CGRA) Certification: Outcomes from the First Six Years.","authors":"Edith Smith, Kimberly Samuels-Bolin, Kristie Bobolis","doi":"","DOIUrl":"","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;Integrating cancer genetics, genomics and cancer risk assessment is increasingly relevant to the care of patients and there is a need for clinicians across practice disciplines to acquire and demonstrate knowledge and clinical competency in cancer genetics and cancer risk assessment. National Consortium of Breast Centers (NCBC's) certification program in Cancer Genetic Risk Assessment (CGRA) is a voluntary nationally (NCCA) accredited, examination-based certification program created to provide the assurance that healthcare providers with certification in CGRA possess the knowledge, skills and competency to provide cancer risk assessment services to patients and families. The certification has achieved recognition by national accrediting organizations (National Accreditation Program for Breast Centers/Commission on Cancer) and payor policies. NCBC's CGRA certification was developed by a multidisciplinary committee of dedicated breast care, oncology, and cancer genetics professionals and approved by NCBC's board of trustees. Testing first became available in May 2020 with testing opportunities provided throughout the year. Testing options include both remote and in-person examination. The target audiences for certification are physicians, advanced practice providers, nurses and other skilled health care practitioners who care for at-risk unaffected and affected patients and their families. Here we describe demographics and outcomes from the first six years of certification examination availability.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;A retrospective cohort of CGRA examination takers was collected from May 2020 (initial examination availability) through December 2025. Analyzed data includes total number of examination takers, pass/fail rates, and professional background and practice setting of the passing cohort. Descriptive statistics were used for analysis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;2020-2025 Total number of CGRA examination takers: 235 Total number (percent) passed: 207/235 (88.1%); failed: 28/235 (11.9%) Professional background of CGRA certificants: APRN - 109/207 (52.7%) RN - 37/207 (17.9%) PA - 30/207 (14.5%) MD - 26/207 (12.6%) RT - 5/207 (2.4%) Practice focus of CGRA certificants: Oncology - 132/207 (63.8%) Surgery - 26/207 (12.6%) High Risk/Genetics - 16/207 (7.7%) Gynecology - 14/207 (6.8%) Breast Center - 12/207 (5.8%) Radiology - 4/207 (1.9%) Primary Care - 1/207 (0.5%) Other - 2/207 (&lt;1%).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;During the first 6 years of CGRA certification eligibility, a notable number of healthcare providers and other healthcare professionals have sought and obtained certification in CGRA through NCBC's CGRA certification program. Seventy percent of all certificant holders have a professional background in nursing. Two-thirds of all certificant holders are advanced practice providers, including advanced practice nurses/nurse practitioners and physician assistants. Twelve perc","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":"22 3","pages":"3"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148280305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}